Navigation Links
Hepatitis B accounts for 40 percent of 'missing' Asian women

In a groundbreaking, sure-to-be-controversial new study, Emily Oster (a graduate student in economics at Harvard University) argues that excess female mortality, such as infanticide, may not be the only cause of uncommonly high male to female ratios in many Asian countries. It has long been observed that the relative number of males is higher in certain Asian countries than in the West, where it is close to unity. A number of authors have suggested that this imbalance reflects neglect of female children and poor conditions for women and, as a result, have argued that as many as 100 million women are "missing."

However, in the forthcoming issue of the Journal of Political Economy, Oster proposes an explanation for some of the observed over-representation of males: the hepatitis B virus. She presents new evidence, consistent with existing scientific literature, that carriers of the hepatitis B virus are 1.5 times more likely to have a male child. This evidence includes both cross-country analyses and natural experimentation based on recent vaccination campaigns. In addition, hepatitis B is common in many Asian countries, particularly China, where some 10 to 15 percent of the population is infected.

Using data on viral prevalence by country as well as estimates of the effect of hepatitis on birth sex, Oster concludes that hepatitis B can account for about 45 percent of the "missing women" ?or, more specifically, for as many as 50 percent of the "missing women" in Egypt and West Asia; under 20 percent in Bangladesh, India, Pakistan and Nepal; and around 75 percent of the "missing women" in China.


'"/>

Source:University of Chicago Press Journals


Page: 1

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
8. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
9. Hepatitis C complicated by morphine withdrawal
10. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
11. Hepatitis E takes a piggyback
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a privately owned ... has just introduced the xCELLigence RTCA S16, which the ideal entry level model for ... computer, the S16can be placed in any standard CO2 tissue culture incubator. The ...
(Date:7/31/2018)... ... July 31, 2018 , ... Lifecycle Biotechnologies, ... Business Development Manager. In this role, Mr. Muzek will lead the company-wide industrial ... growth and expansion. , With over 20 years in business development, Mr. ...
(Date:7/30/2018)... ... 2018 , ... TC Slade, an evidence-based healer, today released ... treated Vitamin D3 on the strength and health of bones. , The ... ALP, a bone-specific enzyme ,     Over 240% increase in collagen levels , ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... July 25, 2018 , ... Vium, Inc. http://www.vium.com ... and Vium Cloud approach to accelerate preclinical drug discovery and development, today announced ... announced the appointment of Jeff Caron to the newly formed role of Senior ...
(Date:7/25/2018)... ... 25, 2018 , ... John McDonald, CEO of ClearObject ... Indiana India Business Council (IIBC), an advocacy group to strengthen economic ties between ... directors, McDonald joins an impressive roster of local and national business leaders from ...
(Date:7/24/2018)... Texas (PRWEB) , ... July 24, 2018 , ... Boval ... to support blood bank reagent suppliers. In Boval’s early days most of the ... were added to produce BSA for diagnostic purposes after gel cards changed that market ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech S.A, a Luxembourg ... for Phase 3 clinical program in Dry Eye Disease. Under the agreement Essex ... $17m allocated towards the first Phase 3 study starting as early as Fall ...
Breaking Biology Technology: